MULTIPLE MYELOMA IN RELAPSE
Clinical trials for MULTIPLE MYELOMA IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA IN RELAPSE trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a booster shot make CAR-T last longer in myeloma?
Disease control Not yet recruitingThis study tests whether adding a drug called NT-I7 to standard CAR-T cell therapy can help the immune cells stay active longer in people with multiple myeloma that has come back or not responded to treatment. About 52 participants will receive either NT-I7 or a placebo after the…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 05:45 UTC
-
Speedy CAR-T cells take on Hard-to-Treat myeloma in first human test
Disease control Not yet recruitingThis early-phase study tests a new CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a person's own immune cells, which are modified in a shorter process than standard C…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Turmeric powerhouse: could a curcumin infusion tame stubborn myeloma?
Disease control Not yet recruitingThis early-stage study tests a new form of curcumin (LipoCurc) given through a vein to people whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the highest safe dose by watching closely for side effects. About 20 adults will take par…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Not yet recruitingThis early-phase study tests a new treatment called SENL103 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. T…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Home injection trial aims to cut hospital trips for myeloma patients
Symptom relief Not yet recruitingThis study looks at whether people with multiple myeloma can safely give themselves the drug daratumumab at home instead of going to the hospital. About 50 patients will alternate between home and clinic doses to compare feasibility and safety. The goal is to make treatment more …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE4 • Sponsor: Odense University Hospital • Aim: Symptom relief
Last updated May 13, 2026 16:03 UTC